Ximena Camacho

Montevideo, MO, Uruguay

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Theranostic Radiotracers for Melanoma Imaging and Therapy: A Comparative Study of Subcutaneous and Intradermal Tumor Models Using DOTA-Re-CCMSH Peptides.

Theranostic Radiotracers for Melanoma Imaging and Therapy: A Comparative Study of Subcutaneous and Intradermal Tumor Models Using DOTA-Re-CCMSH Peptides.

Journal: Cancer biotherapy & radiopharmaceuticals
Published: May 23, 2025

Theranostic Potential of [177Lu]Lu-DOTA-Tocilizumab in Multiple Myeloma: A Preclinical Evaluation.

Theranostic Potential of [177Lu]Lu-DOTA-Tocilizumab in Multiple Myeloma: A Preclinical Evaluation.

Journal: Anti-cancer agents in medicinal chemistry
Published: May 21, 2025

Molecular Imaging of Melanoma VEGF-expressing Tumors through [99mTc]Tc-HYNIC-Fab(Bevacizumab).

Molecular Imaging of Melanoma VEGF-expressing Tumors through [99mTc]Tc-HYNIC-Fab(Bevacizumab).

Journal: Anti-cancer agents in medicinal chemistry
Published: April 08, 2024

Preclinical Evaluation of 99mTc-Labeled LHRH Analog as Cancer Receptor Imaging.

Preclinical Evaluation of 99mTc-Labeled LHRH Analog as Cancer Receptor Imaging.

Journal: Oncology
Published: January 29, 2024

Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors.

Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors.

Journal: Cancer biotherapy & radiopharmaceuticals
Published: January 12, 2024

99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents.

99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents.

Journal: Anti-cancer agents in medicinal chemistry
Published: April 20, 2020

Synthesis of hydrophilic HYNIC-[1,2,4,5]tetrazine conjugates and their use in antibody pretargeting with 99mTc.

Synthesis of hydrophilic HYNIC-[1,2,4,5]tetrazine conjugates and their use in antibody pretargeting with 99mTc.

Journal: Organic & biomolecular chemistry
Published: July 06, 2018

177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.

177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.

Journal: Current radiopharmaceuticals
Published: September 02, 2016

Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.

Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.

Journal: Oncology
Published: June 08, 2016

Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma.

Tocilizumab Labeling with 99mTechnetium via HYNIC as a Molecular Diagnostic Agent for Multiple Myeloma.

Journal: Anti-cancer agents in medicinal chemistry
Published: May 13, 2016

Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody.

Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody.

Journal: Current radiopharmaceuticals
Published: October 13, 2014

Synthesis and evaluation of (99m)Tc chelate-conjugated bevacizumab.

Synthesis and evaluation of (99m)Tc chelate-conjugated bevacizumab.

Journal: Current radiopharmaceuticals
Published: June 21, 2012
Showing 1-12 of 13

Last Updated: 09/26/2026